Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 34: | Line 34: | ||
* Afinitor - Generic: Everolimus | * Afinitor - Generic: Everolimus | ||
* Torisel - Generic: Temsirolimus | * Torisel - Generic: Temsirolimus | ||
| - | =====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl) Inhibitors===== | + | =====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl, RAF kinase) Inhibitors===== |
* [[Gleevec]] - Generic: [[Imatinib]] | * [[Gleevec]] - Generic: [[Imatinib]] | ||
* [[Nexavar]] - Generic: [[Sorafenib]] | * [[Nexavar]] - Generic: [[Sorafenib]] | ||
| Line 50: | Line 50: | ||
* [[Ribociclib]] - brand name [[Kisqali]] | * [[Ribociclib]] - brand name [[Kisqali]] | ||
| - | See also [[Anti-cancer drugs]] | + | See also [[Anti-cancer drugs]], [[Anticancer drugs]] and [[RAF kinase inhibitors]] |
</td> | </td> | ||
</tr> | </tr> | ||
</table> | </table> | ||
__NOTOC__ | __NOTOC__ | ||
Revision as of 07:59, 8 January 2025
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
Anti-prostate cancer
Anti-myeloma
B-Raf Kinase Inhibitor
ChemotherapyDihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitors
Estrogen Receptor Modulator
mTOR inhibitor
Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl, RAF kinase) Inhibitors
Vascular Endothelial Growth Factor Inhibitor
Poly ADP ribose polymerase (PARP) inhibitorsCyclin-dependent kinases inhibitors
See also Anti-cancer drugs, Anticancer drugs and RAF kinase inhibitors |
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
